HOWL
Werewolf Therapeutics Inc

1,045
Mkt Cap
$26.66M
Volume
571,276.00
52W High
$2.38
52W Low
$0.5301
PE Ratio
-0.34
HOWL Fundamentals
Price
$0.5493
Prev Close
$0.5509
Open
$0.54
50D MA
$0.8538
Beta
1.72
Avg. Volume
899,497.59
EPS (Annual)
-$1.63
P/B
0.88
Rev/Employee
$40,978.26
Loading...
Loading...
News
all
press releases
Luke Evnin Sells 30,616 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 30,616 shares of the company's stock in a transaction dated Wednesday, January 14th. The stock was sold at an...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Luke Evnin Sells 58,980 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 58,980 shares of the stock in a transaction dated Monday, January 12th. The stock was sold at an average price of...
MarketBeat·7d ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $11,761.92 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,378 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of...
MarketBeat·12d ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 18,568 Shares
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the business's stock in a transaction on Friday, January 2nd. The shares were sold at an average...
MarketBeat·17d ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $22,448.16 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 35,632 shares of the company's stock in a transaction dated Friday, December 26th. The stock was sold at an...
MarketBeat·21d ago
News Placeholder
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 17,858 Shares
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 17,858 shares of the company's stock in a transaction dated Friday, December 12th. The shares were sold at an...
MarketBeat·1mo ago
News Placeholder
Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock in a transaction on Wednesday, December 10th. The stock was sold at...
MarketBeat·1mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $29,969.63 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock in a transaction dated Thursday, December 11th. The stock was sold at...
MarketBeat·1mo ago
News Placeholder
Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $16,070.96 in Stock
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 16,568 shares of the business's stock in a transaction dated Friday, December 5th. The stock was sold at an...
MarketBeat·1mo ago
<
1
2
...
>

Latest HOWL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.